On Friday, Shares of AT&T, Inc. (NYSE:T), lost -0.75% to $34.54.
AT&T, is committed to keep its customers connected during the forthcoming hurricane season - before, during and after storms - and has one of the industry’s largest and most advanced business continuity and disaster response programs to make sure its networks stay up and running.
No one knows when the next tropical storm or hurricane will hit the coastline. But, AT&T is prepared with one of the nation’s largest and most advanced disaster programs. It invested more than $600 million in the Network Disaster Recovery (NDR) program. And an arsenal of equipment is ready for deployment, counting more than 300 technology and equipment trailers that can be quickly deployed, making it one of the nation’s largest and most advanced disaster programs.
The NDR team works to make sure the right people and tools are in place and ready near the storm impact area. They work with other AT&T response teams, local AT&T network personnel, regional Emergency Operations Centers and Local Response Centers to prepare. Teams are ready to restore and maintain service if disaster strikes.
AT&T is the only telecom company that was re-certified for private-company voluntary disaster preparedness under the Department of Homeland Security’s new international standards.
AT&T standard pre-storm network preparations typically comprise:
- Boosting the wireless network to accommodate raised call volume.
- Testing the high-capacity backup batteries located at cell sites.
- Staging extended battery life and portable generators and maintaining existing fixed generators.
- Topping off generators with fuel at cell sites and switching facilities.
- Using natural gas in some of the permanent generators to eliminate the need to refuel.
- Staging generators in safe locations for immediate deployment once a storm has passed.
AT&T Inc. provides telecommunications services in the United States and internationally. The company operates through two segments, Wireless and Wireline. The Wireless segment offers data and voice services, counting local, long-distance, and network access services, in addition to roaming services to youth, family, professionals, small businesses, government, and business customers.
Shares of MGIC Investment Corp. (NYSE:MTG), inclined 0.37% to $10.85, during its last trading session, hitting its highest level.
MGIC Investment Corporation, declared that Patrick Sinks, Chief Executive Officer, will be discussing the Private Mortgage Insurance industry at the Keefe, Bruyette & Woods 2015 Mortgage Finance Conference. His presentation is planned to start at 1:15 p.m. eastern time on June 2, 2015, and the conference is being held at the Millennium Broadway Hotel in New York City.
MGIC Investment Corporation, through its auxiliaries, provides private mortgage insurance and ancillary services to lenders and government sponsored entities in the United States.
At the end of Friday’s trade, Shares of Centene Corp. (NYSE:CNC), gained 4.05% to $75.34.
Centene Corporation, declared that the Florida Healthy Kids Corporation (FHKC) intends to award its Florida partner, Sunshine Health, a statewide contract to manage healthcare services for children ages five through 18 through the FHKC program. Sunshine Health is one of the largest Medicaid managed care plans in Florida, and presently serves more than 450,000 Medicaid recipients statewide.
Under the projected two-year contract award predictable to commence on October 1, 2015, Sunshine Health will be the only health plan to offer a full pay FHKC insurance product to children in all 11 regions in Florida.
Centene Corporation operates as a diversified, multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. It operates in two segments, Managed Care and Specialty Services.
Finally, KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO), ended its last trade with 19.02% surge, and closed at $0.63.
KaloBios Pharmaceuticals, declared the appointment of Ronald A. Martell, to the position of Executive Chairman. Mr. Martell presently serves as a member of the KaloBios Board of Directors. In this new role, he will work directly with the company’s senior administration team to refine and execute on the planned plan to transition KaloBios to a focused monoclonal antibody company developing therapeutics for orphan oncology indications with high unmet medical need. Mr. Martell will assume the duties of Board Chairman presently held by Ted W. Love, MD, who will continue to act as lead independent director on the KaloBios Board.
Mr. Martell has more than 25 years’ experience building and managing unique businesses in the biotech industry, and most recently served as Chief Executive Officer at Sevion Therapeutics, preceding to which he held similar roles at NeurogesX and at Poniard Pharmaceuticals. Earlier in his career Mr. Martell served as Senior Vice President of Commercial Operations at ImClone Systems, where he built ImClone Systems’ worldwide commercial operations and field sales force to market and commercialize Erbitux® with partners Bristol-Myers Squibb and Merck KGaA. Preceding to joining ImClone Systems, Mr. Martell worked for more than 10 years at Genentech in a variety of leadership positions, the last of which was Group Manager, Oncology. At Genentech, he was responsible for building the company’s oncology franchise counting the launch of Herceptin® for metastatic HER-2 positive breast cancer and Rituxan® for non-Hodgkin’s lymphoma.
KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, develops monoclonal antibody therapeutics for the treatment of cancer in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
